1117-88 High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: Results from the MIRACL trial

[1]  W. Sasiela,et al.  High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial , 2004, Circulation.

[2]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[3]  P. Libby,et al.  High-Dose Atorvastatin Enhances the Decline in Inflammatory Markers in Patients With Acute Coronary Syndromes in the MIRACL Study , 2003, Circulation.

[4]  E. Schaefer,et al.  Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients DOI 10.1194/jlr.M200037-JLR200 , 2002, Journal of Lipid Research.

[5]  A. Sposito,et al.  Statin Therapy in Acute Coronary Syndromes: Mechanistic Insight Into Clinical Benefit , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[6]  M. Ezekowitz,et al.  Effects of Atorvastatin on Stroke in Patients With Unstable Angina or Non-Q-Wave Myocardial Infarction: A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Substudy , 2002, Circulation.

[7]  J. Liao,et al.  Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[8]  A. Sharrett,et al.  Coronary Heart Disease Prediction From Lipoprotein Cholesterol Levels, Triglycerides, Lipoprotein(a), Apolipoproteins A-I and B, and HDL Density Subfractions: The Atherosclerosis Risk in Communities (ARIC) Study , 2001, Circulation.

[9]  J. Plana,et al.  The use of statins in acute coronary syndromes: The mechanisms behind the outcomes , 2001, Current atherosclerosis reports.

[10]  C. Destache,et al.  Potential Influence of Timing of Low‐Density Lipoprotein Cholesterol Evaluation in Patients with Acute Coronary Syndrome , 2001, Pharmacotherapy.

[11]  K. Parhofer,et al.  Effect of atorvastatin on low-density lipoprotein subtypes in patients with different forms of hyperlipoproteinemia and control subjects. , 2001, Metabolism: clinical and experimental.

[12]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[13]  Michael F. Oliver,et al.  Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study. , 2001, Indian heart journal.

[14]  G. Thorgeirsson,et al.  Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S) , 1998, Circulation.

[15]  M. Ezekowitz,et al.  Rationale and design of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) study that evaluates atorvastatin in unstable angina pectoris and in non-Q-wave acute myocardial infarction. , 1998, The American journal of cardiology.

[16]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.